Particle.news
Download on the App Store
8 ARTICLES
·
last wk.

Sanofi Agrees $9.1B Acquisition of Blueprint Medicines to Bolster Rare Immunology Pipeline

Financed through cash reserves alongside new debt, the acquisition is slated to close in the third quarter pending regulatory approval followed by shareholder sign-off.

Image
Image
Sanofi will pay $129 per share in cash, the companies said in a statement Monday.
Image

Overview

  • Sanofi will pay $129 per share in cash for Blueprint, valuing the deal at $9.1 billion and reflecting a 27 percent premium over the biotech’s recent closing price.
  • Blueprint shareholders will receive one non-tradeable contingent value right per share, entitling them to up to $400 million in milestone payments tied to BLU-808’s development and regulatory milestones.
  • The deal brings Blueprint’s approved systemic mastocytosis treatment Ayvakit/Ayvakyt and pipeline candidates including elenestinib and the oral KIT inhibitor BLU-808 into Sanofi’s portfolio.
  • The transaction, expected to complete in Q3 2025, is contingent on regulatory approval and shareholder sign-off and will be financed using existing cash reserves alongside new debt.
  • This acquisition reinforces Sanofi’s strategic shift toward precision medicine for rare diseases and immunology, building on recent purchases of Vigil Neuroscience and Inhibrx.